• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Aethlon Medical Inc.

    8/15/24 4:32:05 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care
    Get the next $AEMD alert in real time by email
    DEFA14A 1 aethlon_defa14a.htm ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No.__)

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under § 240.14a-12
       
    AETHLON MEDICAL, INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
     

    Payment of Filing Fee (Check all boxes that apply):

    ☒   No fee required

    ☐   Fee paid previously with preliminary materials

    ☐   Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     1 

     

     

     

     

    You invested in AETHLON MEDICAL, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on September 27, 2024. Get informed before you vote View the Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to September 15, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID - JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 1 OF 322,224 148,294 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX AETHLON MEDICAL, INC. 2024 Annual Meeting Vote by September 26, 2024 11:59 PM ET Vote in Person at the Meeting* September 27, 2024 8:00 AM PST https://www.iproxydirect.com/aemd

     

     
     

     

    Voting Items Board Recommends For 1. Election of Directors Nominees: 1A Edward G. Broenniman For James B. Frakes 1B For Nicolas Gikakis 1C For Angela Rossetti 1D For Chetan S. Shah, M.D. 1E For To ratify the appointment of Haskell & White LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2025. 2 For To approve an amendment to our 2020 Equity Incentive Plan, as amended, to increase the number of shares of the Company's common stock authorized for issuance thereunder by 3,000,000 shares. 3 For To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. 4 For To approve the adjournment of the Annual Meeting to another place, or a later date or dates, if necessary or appropriate, to solicit additional proxies in the event we have not received sufficient votes in favor of any of the foregoing proposals. 5 NOTE: Such other business as may properly come before the meeting or any adjournment thereof. THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID - JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting . We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date . AETHLON MEDICAL, INC. 2024 Annual Meeting Vote by September 26, 2024 11:59 PM ET

     

     

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD

    DatePrice TargetRatingAnalyst
    7/7/2025$1.50Neutral
    H.C. Wainwright
    6/25/2021$5.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AEMD
    SEC Filings

    View All

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 5:10:41 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/12/26 4:15:44 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Aethlon Medical Inc.

    DEFA14A - AETHLON MEDICAL INC (0000882291) (Filer)

    1/27/26 4:15:26 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million

    SAN DIEGO, Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 1,042,820 shares of common stock, in a private placement priced at-the-market under Nasdaq rules. The combined effective offering price for each share of common stock (or pre-funded warrant in-lieu thereof) and accompanying wa

    12/5/25 9:15:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Aethlon Medical with a new price target

    H.C. Wainwright resumed coverage of Aethlon Medical with a rating of Neutral and set a new price target of $1.50

    7/7/25 8:15:50 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Aethlon Medical with a rating of Buy and set a new price target of $9.00 from $5.00 previously

    6/25/21 6:10:29 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

    HC Wainwright & Co. initiated coverage of Aethlon Medical with a rating of Buy and set a new price target of $5.00

    6/1/21 8:48:18 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Shah Chetan covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,356 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:43:21 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Gikakis Nicolas covered exercise/tax liability with 179 shares, decreasing direct ownership by 7% to 2,357 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:42:37 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Director Broenniman Edward G covered exercise/tax liability with 89 shares, decreasing direct ownership by 3% to 2,807 units (SEC Form 4)

    4 - AETHLON MEDICAL INC (0000882291) (Issuer)

    1/2/26 6:41:25 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026

    SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2025, at 4:15 p.m. ET on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10206585/1034

    2/4/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Aethlon Medical, Inc. (Amendment)

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    1/13/22 10:30:14 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Aethlon Medical, Inc.

    SC 13G - AETHLON MEDICAL INC (0000882291) (Subject)

    6/15/21 10:01:32 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - AETHLON MEDICAL INC (0000882291) (Subject)

    2/22/21 9:53:48 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care